Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
NATO needs Ukraine's 'adaptation DNA' and an 'HOV lane' for new war tech, top commander says - 2Artemis 2 astronauts arrive at Kennedy Space Center ahead of NASA's historic launch around the moon
- 3Soldiers seize power in Guinea-Bissau and detain the president
- 4'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- 5Ukrainian drones hit all three Baltic States − did Russia redirect them?
- Explosions at Burundi ammunition depot kill civilians, witnesses say
- National health ranking puts Georgia near bottom of list. Here's why
- People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
- Figure out How to Recognize Early Indications of Depressions
- Israeli forces kill one person in series of attacks on southern Lebanon
- Your big brain makes you human – count your neurons when you count your blessings
- 'Wicked: For Good' was filmed at this surreal National Park in Egypt
- Blood pressure drug recalled for possible cross-contamination
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
